Risk factor
Very poor trading liquidity
Profitability factor
Very low or no dividends
About
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is of fair value on EV/EBITDA, tradin
Target Price
The average target price of HLS.TO is 7.3 and suggests 59% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell